NICE Pembrolizumab Recommendation for Locally A...

By HEOR Staff Writer

March 25, 2026

NICE Pembrolizumab recommendation offers a major advance for adults with resectable locally advanced head and neck squamous cell carcinoma. This update provides an evidence-based overview of the final draft guidance issued by NICE recommending pem...
PEPFAR TB Impact: Averting Millions of Cases and Deaths Among HIV Patients
Citation Analysis of Real-World Evidence in Medicare Drug Price Negotiations
Serplulimab Lung Cancer Treatment: Evaluation of Clinical and Economic Impact...
Biomarin Withdraws Voxzogo Reimbursement Application in the Netherlands
FDA Warning Letter Novo Nordisk Reveals Serious Compliance Failures in Advers...
Methodological Gaps in Economic Evaluations of Vaccines: A Systematic Review
Tirzepatide Cost Effectiveness: A Winning Strategy for Type 2 Diabetes Manage...
Novo Nordisk Announces Semaglutide Price Reduction to Improve Patient Access
NICE Approves Ruxolitinib Cream for Treating Vitiligo with Facial Involvement
Exploring MFN Policy Effectiveness in Drug Pricing and Innovation
Zorginstituut Nederland’s Lecanemab Health Insurance Rejection: Implica...
Revised MenACWY Vaccination Strategy for Adolescents in Germany